Moteur de recherche d’entreprises européennes
Financement de l’UE (6 871 189 €) : Avancement d’un vaccin à base de GMMA contre la salmonellose invasive non typhoïde dans le cadre d’un essai de phase 1 en Europe et en Afrique subsaharienne Hor14/06/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Avancement d’un vaccin à base de GMMA contre la salmonellose invasive non typhoïde dans le cadre d’un essai de phase 1 en Europe et en Afrique subsaharienne
Invasive non-typhoidal Salmonellosis (iNTS) is an important emerging Neglected Infectious Disease in resource-poor settings of sub-Saharan Africa (sSA). No vaccine is currently available. Estimated 263,000 iNTS deaths per year in <5 year olds, a 20% case fatality rate, difficult diagnosis and increasing antibiotic resistance strongly advocate for rapid development of an effective vaccine. Vacc-iNTS bridges the gap between preclinical and early clinical development of a novel vaccine against iNTS, based on GMMA (Generalized Modules for Membrane Antigens) from the most common African iNTS serotypes (Typhimurium and Enteritidis). The highly cost-effective GMMA-technology, developed by partner 2, is based on outer membrane blebs released by genetically modified bacteria. Clinical proof-of-concept for the GMMA-technology was achieved with a Shigella sonnei vaccine in European and African adults. In animals, iNTS-GMMA were highly immunogenic and induced antibodies with bactericidal activity against African iNTS strains. Simple, robust and scalable manufacturing processes for iNTS-GMMA, suited for sSA, have been developed. Vacc-iNTS proposes GMP manufacturing of clinical lots followed by a two-stage Phase 1 trial in healthy European and African adults to investigate safety and immunogenicity of the iNTS-GMMA vaccine. Analysis include serum antibody levels and functionality, cellular responses, transcriptomics and data integration through a systems biology approach. Sero-epidemiological analysis will be conducted to provide essential data for future Phase 2 and 3 trials. Vacc-iNTS will also strengthen a collaborative network of iNTS experts from academia, industry and non-profit including partners from disease-endemic countries of sSA. The network will generate data to accelerate further vaccine development, enhance awareness, drive advocacy and vaccine deployment in limited-resources disease-endemic countries, tackling major roadblocks in advancing a vaccine against iNTS.
| Fondazione Achille Sclavo Organizzazione NON Lucrativa Di Utilita Sociale | 0,00 € |
| Glaxosmithkline Biologicals SA | 0,00 € |
| GSK Vaccines Institute FOR Global Health Srl | 1 576 515 € |
| Instituut Voor Tropische Geneeskunde | 31 297 € |
| Kenya Medical Research Institute | 107 575 € |
| Kwame Nkrumah University OF Science AND Technology Kumasi | 194 226 € |
| MMGH Consulting GmbH | 20 000 € |
| Sclavo Vaccines Association | 1 152 312 € |
| The Chancellor, Masters and Scholars of the University of Oxford | 2 227 289 € |
| The Chancellor Masters and Scholars of the University of Cambridge | 545 943 € |
| The University of Liverpool | 432 035 € |
| Universita Degli Studi Di Siena | 341 018 € |
| Universite Ouaga I Professeur Joseph KI-Zerbo | 192 980 € |
| University OF Malawi | 0,00 € |
| University OF Otago | 50 000 € |
https://cordis.europa.eu/project/id/815439
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.